Developing new pharmaceuticals entails a long period of over 10 years, as well as a diverse process ranging from basic research to marketing. To free patients from concerns over their illness as soon as possible, we must improve the efficiency of our R&D process. To this end, Santen conducts drug discovery and clinical development on a global basis, utilizing the facilities of the Santen Group and related organizations worldwide. In this way, we are improvin our system of producing new products that meet global medical needs in a timely manner.
In terms of research activities, within Santen we have concentrated our basic research, non-clinical studies, and drug formulation research at Nara Research and Development Center, so as to integrate the knowledge of our various sections and create better products. We are also working to speed up our decision-making. With external organizations, we have built a system to facilitate information exchange and collaborations through our own networks. In 2011, Santen purchased Santen S.A.S. (formally known as Novagali), a French ophthalmic pharmaceutical company that has an excellent R&D capability and drug formulation technologies in the dry eye field. This purchase has reinforced Santen's development pipelines, enhancing its international competitiveness in the ophthalmic field.
To speed up clinical development, Santen has relocated its hub to the United States (Santen Inc.), where clinical trials can be conducted in a relatively short time. To improve the quality and efficiency of clinical development, we are building a system to conduct early-stage clinical development in the United States, while conducting the late-stage clinical development in Japan, the United States, Europe, China and other Asian countries, as well as in other emerging countries.
To promote our network-based drug discovery and global R&D efforts, Santen is placing significant emphasis on strengthening our relationships with universities, research organizations and other pharmaceutical firms to produce new treatments for patients around the World. We hope such relationships will lead to the discovery and launch of novel therapies for severe dry eye syndrome, glaucoma, diabetic macular oedema and uveitis, a condition with limited treatment options.